Drug Type Antibody drug conjugate (ADC) |
Synonyms Anti-EGFRvIII-DM1 immunoconjugate, AMG 595 |
Target |
Mechanism EGFRvIII antagonists(Epidermal growth factor receptor variant III antagonists), Tubulin inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC35H48ClN3O10S |
InChIKeyANZJBCHSOXCCRQ-FKUXLPTCSA-N |
CAS Registry139504-50-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma Multiforme | Phase 1 | US | 01 Feb 2012 | |
Glioblastoma Multiforme | Phase 1 | AU | 01 Feb 2012 | |
Recurrent Malignant Glioma | Phase 1 | US | 01 Feb 2012 | |
Recurrent Malignant Glioma | Phase 1 | AU | 01 Feb 2012 |